Effect of Metformin as Add-on Therapy in Levodopa Treated Parkinson's Disease Patients

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

December 29, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

July 20, 2025

Conditions
Parkinson Disease
Interventions
DRUG

Metformin

Metformin's chemical name is 1,1-Dimethylbiguanide, a molecular formula of C4H11N5. Beyond its well established antihyperglycemic impact, metformin demonstrated anti-oxidant and anti-inflammatory activities contributing its potential benefits in conditions associated with inflammation and oxidative stress. Furthermore, metformin rapidly crosses the blood brain barrier and disperses into several brain regions presenting an ideal therapeutic option for the treatment of PD.

OTHER

placebo

placebo of tab. Metformin of same shape

Trial Locations (1)

1217

BSMMU, Dhaka

All Listed Sponsors
lead

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

OTHER

NCT07055958 - Effect of Metformin as Add-on Therapy in Levodopa Treated Parkinson's Disease Patients | Biotech Hunter | Biotech Hunter